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ABSTRACT
Objective To evaluate the risk of stroke and myocardial
infarction (MI) in adult patients with systemic lupus
erythematosus (SLE) through a systematic review and
meta-analysis.
Methods We searched MEDLINE and EMBASE from
inception to May 2020 to identify observational studies
(cohort and cross-sectional) that evaluated risk of stroke
and MI in adult patients with SLE compared with the general
population or healthy controls. Studies were included if they
reported effect-size estimates that could be used for
calculating pooled-effect estimates. Random-effects
models were used to calculate pooled risk ratios (RRs) and
95% CIs for stroke and MI. Heterogeneity quantified by the I2
test and sensitivity analyses assessed bias.
Results In total, 26 studies were included in this meta-
analysis: 14, 5 and 7 studies on stroke, MI and both stroke
and MI, respectively. The pooled RR for ischaemic stroke
was 2.18 (95% CI 1.78 to 2.67; I2 75%), intracerebral
haemorrhage 1.84 (95% CI 1.16 to 2.90; I2 67%),
subarachnoid haemorrhage 1.95 (95% CI 0.69 to 5.52; I2
94%), composite stroke 2.13 (95% CI 1.73 to 2.61; I2 88%)
and MI 2.99 (95% CI 2.34 to 3.82; I2 85%). There was no
evidence for publication bias, and sensitivity analyses
confirmed the robustness of the results.
Conclusions Overall, patients with SLE were identified to
have a twofold to threefold higher risk of stroke and MI.
Future research on the interaction between known SLE-
specific modifiable risk factors and risk of stroke and MI to
support development of prevention and treatment strategies
are needed.
PROSPERO registration number CRD42018098690.
INTRODUCTION
Systemic lupus erythematosus (SLE) is
a chronic autoimmune disorder characterised
by alternating periods of flares and remission,
and irreversible organ damage associated with
disease activity.1 The skin, joints, heart, kid-
neys, central nervous system and haematolo-
gic system are some of the most commonly
affected organs.2 3 Organ damage has been
associated with increased morbidity and
mortality.4 Although recent data suggest that
mortality decreased in patients with SLE over
the last 30 years, mortality due to cardiovascu-
lar disease (CVD) has remained high,5–8 an
estimated twofold to threefold increased risk
of CVD-associated mortality compared with
the general population.9–11
Stroke and myocardial infarction (MI) are
major CVD events that are potentially life-
threatening.12 Understanding the magnitude
of stroke and MI risk in patients with SLE and
characterising patients at highest risk would
support the development of strategies for pre-
venting and treating or modifying risk factors.
Patients with SLE have an increased risk of
stroke10 13 and MI.10 Evidence includes
a meta-analysis of cohort studies published
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What is already known about this subject?
► Systemic lupus erythematosus (SLE) is a chronic
autoimmune disorder associated with increased
comorbidities.
► Epidemiological studies have suggested an increased
risk of cardiovascular events, including stroke and
myocardial infarction (MI), in patients with SLE.
What does this study add?
► The pooled relative risk of stroke (intracerebral
haemorrhage, ischaemic stroke and subarachnoid
haemorrhage) and MI from epidemiological studies
was found to be twofold to threefold higher among
patients with SLE compared with the general
population or healthy controls.
► This magnitude of risk was 1.84-fold higher for
intracerebral haemorrhage, 1.95-fold for subarachnoid
haemorrhage, 2.13-fold for composite stroke, 2.18-fold
for ischaemic stroke and 2.99-fold for MI.
How might this impact clinical practice?
► This study confirms the need for treatment strategies
that consider prevention and treatment of modifiable
cardiovascular risk factors in addition to SLE
management.
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prior to 2015 that compared patients with SLE with the
general population.13 There are no recent meta-analyses
that evaluate both stroke and MI across multiple observa-
tional study types to estimate pooled risk.
We aimed to synthesise evidence from published obser-
vational studies reporting risk of major cardiovascular
events in adults with SLE compared with the general
population or healthy controls.14 We report our findings
on the risk of stroke and MI in patients with SLE. We also
evaluate the role of age and sex in stroke and MI risk.
METHODS
Search strategy
This study was conducted in accordance with the Meta-
analysis of Observational Studies in Epidemiology and
the Preferred Reporting Items for Systematic reviews
and Meta-Analyses guidelines for conducting and
reporting systematic reviews.15 16 The study protocol
was prepared and published via the International Pro-
spective Register of Systematic Reviews, PROSPERO
(#CRD42018098690).14 Searches for full-text reports
containing original data were run in Ovid MEDLINE
and EMBASE until March 2018; an additional update
search was run until May 2020. The detailed search
strategy is available in online supplemental table S1.
We also searched the reference lists of articles and
contacted experts in the field.
Eligibility criteria
We included full publications of observational studies
(cohort and cross-sectional studies) published in Eng-
lish reporting the risk of CVD outcomes in adult
patients with SLE compared with the general popula-
tion or healthy controls. Patients with SLE were identi-
fied by International Classification of Diseases (ICD)
codes, American College of Rheumatology (ACR) cri-
teria or clinician-confirmed diagnosis.17 18 The out-
comes reported in this manuscript include fatal and
non-fatal stroke (including subtypes) and MI events.
Studies were included if they reported one of the fol-
lowing measures of relative risk: HR, rate ratio, risk
ratio (RR), OR, incidence rate ratio, proportionate
morbidity ratio, standardised mortality rate or standar-
dised incidence rate with 95% CIs. Abstracts of unpub-
lished studies were excluded as data were not reported
to support formal comparison.
Screening and abstraction process
Two-stage screening (title/abstract and full-text screen-
ing), data extraction and risk of bias assessment were
performed independently by two reviewers (NP and
LN); disagreement was resolved by consensus involving
a third reviewer (JL). Studies that met the eligibility cri-
teria and reported original data were included in the
review. Data on study characteristics and the effect mea-
sure for outcomes of interest (fatal and non-fatal events)
were extracted.
Risk of bias and quality assessment
The risk of bias of included studies was estimated using
the Newcastle-Ottawa Scale19 and an SLE-specific 12-
point scale developed for use in previous SLE systematic
reviews.8 11 13 20–23 The SLE-specific 12-point scale scores
quality in five domains: (1) source of study sample (popu-
lation-based and clinic-based), (2) cohort type (inception
and non-inception), (3) SLE definition (ACR classifica-
tion criteria for SLE, ICD codes and medical record
review), (4) length of SLE exposure (≥10 or <10 years,
≥5 or <5 years or not defined) and (5) ascertainment of
outcome (medical record review, ICD code only and
exclusion of prevalent outcomes at baseline) (online
supplemental table S2). The Newcastle-Ottawa Scale
assesses study quality in three domains: (1) selection of
study groups, (2) comparability of cohorts by design or
analysis and (3) ascertainment of outcomes of interest
(online supplemental table S3). Studies were classified
as having low, moderate or high risk of bias based on
results from domains in both scales.
Statistical analysis
We performedmeta-analyses for stroke andMI where two
or more studies with a low risk of bias reported usable
data. One study was selected for inclusion in the meta-
analysis based on study quality, population size and
length of study period if there were two studies that
reported findings from overlapping populations.
ORs, HRs, rate ratios, standardised incidence ratios and
standardised mortality ratios were considered equal esti-
mates assuming rare occurrence24 and referred to as ‘risk
ratios’ throughout this publication. The most adjusted
RR was used. A DerSimonian and Laird25 random-
effects model was fit to calculate the pooled RR and
95% CIs for all outcomes.
Heterogeneity was measured using the Cochran’s
Q statistic with statistical significance set at p<0.10 and
quantified by the I2 test. Publication bias was assessed with
both funnel plots and the Egger’s test.26
Robustness of the results was assessed by the leave1out
function,27 which examined the effect of removing indi-
vidual studies on pooled estimates. Several sensitivity ana-
lyses were performed, including least-adjusted analysis,
studies published during or after 2014, studies published
before 2014, studies with low risk of bias, studies reporting
non-fatal events, studies reporting non-fatal/fatal events,
studies previously excluded because the populations over-
lapped with another study; and excluding cross-sectional
studies. All analyses were conducted in R version 3.5.1
using the packages metafor and forestplot.
We describe reported RRs for the patient subgroups of
age and sex, for which data were available from specific
studies. Due to the paucity of data, no meta-analyses were
conducted for subgroups.
Patient and public involvement
No patients or the public were involved in setting the
research question or outcome measures, nor in the
RMD Open
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design and implementation of the study. However, the
dissemination plan targets a wide audience including
members of the public, patients, health professionals
and experts in the speciality through various channels




The original search of the two electronic databases iden-
tified 3252 records; 2569 articles remained after dupli-
cates were removed. Of these, 2400 were excluded after
screening titles and abstracts. After full-text review, 23
publications reporting on stroke and MI were retained
for inclusion in this report (figure 1). The updated search
identified 612 records; 420 articles remained after dupli-
cates were removed. Of these, 372 were excluded after
screening titles and abstracts. After full-text review, three
additional publications reporting on stroke and MI were
retained, bringing the total for inclusion to 26 publica-
tions. A list of excluded studies, with reasons, is outlined
in online supplemental table S4.
Study characteristics
Characteristics of the 26 included studies5–7 28–50 are
summarised in table 1. There were 23 cohort studies
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included in quantitative 
analysis (n=26)








•   Wrong/no comparison: 77
•   Wrong outcome: 50
•   No usable data: 29
•   Non-English: 9
•   Wrong population: 9
•   Too few patients (n<100): 2
•   Review article: 1
•   Wrong study design: 1




Figure 1 Flow diagram of the systematic literature review process to evaluate the risk of stroke and MI in patients with SLE
compared with the general population or healthy controls. MI, myocardial infarction; SLE, systemic lupus erythematosus.
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Twenty-four studies reported the number of patients
with SLE assessed (N=249 687) and 15 studies reported
the number of general population/healthy controls
assessed (N=50 310 715). Studies were conducted in
Asia (n=7), Europe (n=10), North America (n=8) or mul-
tiple countries (including centres in Europe, North
America and Asia; n=1). Study durations ranged from 1
to 43 years. The percentage of female patients ranged
from 78% to 100%. Average age, reported in 15 studies,
ranged from 31 to 56 years. Bias was assessed to be low in
19 studies6 28–32 34–37 39–41 43–46 and as moderate in two
studies.5 7 Five studies were assessed as having high risk of
bias, three of which were cross-sectional studies33 38 47 and
two were cohort studies.42 49 The risk of bias assessment
for included studies is summarised in online supplemental
table S5.
Stroke
Meta-analyses were performed for the following stroke
outcomes: composite stroke, subarachnoid haemor-
rhage, intracerebral haemorrhage and ischaemic stroke.
No meta-analysis was performed for haemorrhagic stroke
(n=1) and unspecified stroke (n=2), only one of the two
studies had low risk of bias.
Composite stroke
Composite stroke was reported in 16 studies: six studies
evaluated fatal or non-fatal events,28 30 33 35 36 42 five
evaluated non-fatal events38 40 44 45 47 and five evaluated
fatal events.5–7 Five studies were not included in the main
meta-analysis: four had overlapping populations with
other studies5 30 33 40 and one only reported data by age
group.47 Nine of the 11 studies included had low risk of
bias (online supplemental table S5).
Composite stroke was identified by ICD-8, ICD-9 and
ICD-10 codes in 12 of 16 studies. In the remaining three
studies, stroke was identified by unreported read codes,
physician diagnosis, National Survey of Stroke criteria
or Biobank database based on ICD-10 codes (online
supplemental table S6). The ICD codes used to create
the composite stroke endpoint were specific to each study
and are listed in online supplemental table S6.
SLE was associated with an increased risk of composite
stroke, with a pooled RR of 2.13 (95% CI 1.73 to 2.61; I2
for heterogeneity 88.3%; df=10; p≤0.001) (figure 2A).
Subarachnoid haemorrhage
Subarachnoid haemorrhage was reported in six studies:
three studies evaluated fatal/non-fatal events,28 31 43 two
studies evaluated non-fatal events38 45 and one study eval-
uated fatal events.5 Two studies were not included in the
meta-analysis because they did not provide usable 95%
CIs.5 31 Three of the four studies included had low risk of
bias (online supplemental table S5).
Subarachnoid haemorrhage was identified by ICD-8,
ICD-9 and ICD-10 codes in all studies. The ICD codes
used were the same in all studies that reported them
(online supplemental table S6).
Risk of subarachnoid haemorrhage did not significantly
increase in patients with SLE, with a pooled RR of 1.95
(95% CI 0.69 to 5.52; I2 for heterogeneity 94.4%; df=3;
p<0.001) (figure 2B).
Intracerebral haemorrhage
Intracerebral haemorrhage was reported in five studies:
two studies evaluated fatal/non-fatal events28 42 and three
studies evaluated non-fatal events.38 45 46 One study was
not included in the meta-analysis because the population
overlapped with another study.46 Of the four studies
included, two had low risk of bias (online supplemental
table S5).
Intracerebral haemorrhage was identified by ICD-8,
ICD-9 and ICD-10 codes in four of five studies. The
codes used were similar in all studies that reported them
and are listed in online supplemental table S6. In one
study, physician diagnosis confirmed case identification.
SLE was associated with an increased risk of intracer-
ebral haemorrhage, with a pooled RR of 1.84 (95% CI
1.16 to 2.90; I2 for heterogeneity 67.4%; df=3; p<0.0027)
(figure 2C).
Ischaemic stroke
Ischaemic stroke was reported in nine studies: three stu-
dies evaluated fatal/non-fatal events,28 29 42 five studies
evaluated non-fatal events32 38 40 45 46 and one study
evaluated fatal events.5 Four studies were not included
in the meta-analysis, two of which had overlapping study
populations,45 46 one did not report a usable 95%CI5 and
one reported data only for a subpopulation.40 Of the five
studies included, three had low risk of bias (online
supplemental table S5).
Ischaemic stroke was identified by ICD-8, ICD-9 and
ICD-10 codes in seven of nine studies. The codes used
were similar in all studies that reported them and are
listed in online supplemental table S6. In the remaining
studies, physician diagnosis or national insurance claims
data confirmed case identification.
SLE was associated with an increased risk of ischaemic
stroke, with a pooled RR of 2.18 (95% CI 1.78 to 2.67; I2
for heterogeneity 75.4%; df=4; p≤0.001) (figure 2D).
Myocardial infarction
MI was reported in 12 studies: six studies evaluated fatal/
non-fatal events29 30 34–36 39 and six studies evaluated non-
fatal events.37 41 47–50 Four studies were not included in
the meta-analysis: two because they reported data only for
a subpopulation,41 47 one because it only reported data
on lupus nephritis (LN)34 and one owing to population
overlap with another study.30 Of the eight studies
included, all but one had low risk of bias49 (online
supplemental table S5).
MI was identified by ICD-8, ICD-9 and ICD-10 codes
in 8 of 12 studies. The codes used were similar in all
studies that reported them and are listed in online
supplemental table S6. In the remaining studies,
a combination of WHO criteria, hospital data, Biobank
RMD Open
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database based on ICD-10 codes or autopsy evidence
confirmed identification. One study did not report how
MI was identified.
SLE was associated with an increased risk of MI, with
a pooled RR of 2.99 (95% CI 2.34 to 3.82; I2 for hetero-
geneity 85.7%; df=7; p≤0.001) (figure 2E).
Sensitivity analyses and heterogeneity
The leave1out method and various sensitivity analyses
confirmed the robustness of the results (table 2, online
supplemental table S7).
In terms of the leave1out function, only one analysis
showed a statistically significant effect of removing an
individual study. Removal of a cross-sectional study38 eval-
uating subarachnoid haemorrhage increased the relative
risk identified in the base case from 1.95 to 3.06 (RR 3.06,
95% CI 1.87 to 5.02).
The base-case analyses identified composite stroke, sub-
arachnoid haemorrhage, intracerebral haemorrhage,
ischaemic stroke and MI as being statistically significantly
increased in persons with SLE compared with the general
population. Results of all sensitivity analyses for compo-
site stroke remained significant. For subarachnoid hae-
morrhage, intracerebral haemorrhage and ischaemic
stroke, a number of sensitivity analyses resulted in relative
risks that were, in general, higher than the base case but
statistically non-significant. We observed this when sensi-
tivity analyses were restricted to studies reporting only on
non-fatal/fatal events, only low risk of bias studies, only
studies published during or after 2014 and excluding
cross-sectional studies. For MI, three of the sensitivity
analyses resulted in a lower relative risk that was not
statistically significant (including only studies reporting
on non-fatal/fatal events, only studies published before
2014 and only studies reporting on non-fatal events).
Visual examination of the funnel plots showed evi-
dence of publication bias, which was supported by the
Egger’s test for ischaemic stroke (p=0.001) but not for
composite stroke (p=0.885), subarachnoid haemor-
rhage (p=0.686), intracerebral haemorrhage (p=0.265)
and MI (p=0.500).
Subgroup evaluation of age and sex
Eight studies reported the relative risk of stroke stratified
by age.28 29 36 42 44–47 Data suggest that risk of stroke
increases with age in SLE and non-SLE populations.
Patients with SLE have a higher relative risk of stroke,
particularly in younger age groups, compared with age-
matched population controls. In patients with SLE aged
<30 years, RRs ranged from 14.5 to 53.9, and in patients
aged >70 years, RRs ranged from 0.53 to 1.76, depending
on type of stroke and study design (online supplemental
figure S1).
Four studies reported the relative risk of MI stratified by
age; however, differences in age group boundaries and
small numbers of patients with SLE within groups meant
that the data could not be summarised.29 30 41 47 It was not
possible to summarise the relative risk of stroke and MI
stratified by sex due to the small numbers of male patients
included in the studies.
Figure 2 Forest plots of pooled risk ratios for stroke and MI outcomes in adult patients with SLE compared with the general
population or healthy controls: (A) composite stroke, (B) subarachnoid haemorrhage, (C) intracerebral haemorrhage, (D) ischaemic
stroke, (E) MI. MI, myocardial infarction; SLE, systemic lupus erythematosus.
Lupus
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DISCUSSION
In this meta-analysis of 26 real-world observational stu-
dies, patients with SLE had a twofold increase in risk of
stroke and threefold increase in risk of MI compared with
the general population or healthy controls. To our knowl-
edge, this is the first meta-analysis to assess the risk of both
stroke andMI across multiple observational study types in
adult patients with SLE compared with the general popu-
lation or healthy controls.
Rheumatologists are increasingly recognising the risk
of CVD as a comorbid disease in patients with SLE. Recent
2019 guidelines from the EULAR recommend assessment
of CVD risk and initiation of preventive strategies for
patients with SLE when necessary.51 Because the develop-
ment of CVD could result in decreased health-related
quality of life52 and early mortality,9 53 health education
and risk factor modification are important for this
patient population.
Our findings are consistent with a published meta-
analysis for stroke in patients with SLE that included
studies up to June 2015.13 The increased risk of compo-
site stroke (RR 2.13), intracerebral haemorrhage (RR
1.84) and ischaemic stroke (RR 2.18) are consistent with
findings reported by Holmqvist et al.13 However, the
higher number of studies included in our meta-analysis
meant increased precision, evidenced by smaller CIs.
The increased risk of subarachnoid haemorrhage (RR
1.95) in our analysis is lower than that reported by
Holmqvist et al13 (RR 3.85) because our analysis includes
a cross-sectional study published in 2005 that reports
a low RR (0.53).38 When we excluded this study in the
sensitivity analysis, the RR increased to 3.50 (95%CI 2.24
to 5.48), similar to that reported by Holmqvist et al.13
Our analyses confirm that the relative risk of stroke is
higher in younger patients with SLE compared with age-
matched controls and corroborate findings from
a previous systematic review.13 Although the underlying
pathogenesis of increased stroke risk in patients with SLE
is the subject of ongoing research, accelerated athero-
sclerosis likely plays a role.54–56 Accelerated atherosclero-
sis has also been shown to be associated with LN, which
often develops at a young age and is also associated with
increased CVD risk.57 58 A previous study found that
patients with SLE and a history of LN had twice the rate
of carotid plaque as age-matched patients with SLE with-
out LN. Patients with SLE and no LN did not differ from
age-matched non-SLE controls regarding carotid
plaques.58 Accelerated atherosclerosis is often considered
to be the primary cause of increased CVD risk in patients
with SLE.59
Our study is strengthened by a rigorousmethodological
approach based on international guidelines for conduct
and reporting of systematic reviews and meta-analyses.
The study design included a comprehensive search of
multiple databases, reducing the likelihood of omitting
evidence reported in key studies. The study selection
criteria ensured that studies with overlapping popula-
tions were evaluated only once, ensuring greater
confidence in reported relative risk estimates. Our study
has some limitations. We identified heterogeneity across
the evaluated studies that may be a result of variations in
population characteristics, control group selection and
risk measure reported. An additional source of heteroge-
neity may result from the extent to which the SLE and
comparison populations were matched for CVD risk fac-
tors. Some studies matched the population for a wide
range of risk factors or adjusted for them in the analysis,
while others only matched or adjusted for a limited num-
ber of risk factors. However, multiple sensitivity analyses
confirmed the increased risk of stroke and MI in patients
with SLE. Because of limited data, meta-analyses could
not be performed on patient subgroups.
In addition to age, other known MI and stroke risk
factors and SLE-related factors are likely to be important
in explaining the observed elevated risk. Of SLE-related
factors, disease duration and damage, antiphospholipid
antibodies, renal and neuropsychiatric disease and ster-
oids have been linked to increased risk of CVD events.59 60
In this work, although subgroup analyses including these
risk factors were not possible owing to limited data, our
meta-analysis included two studies that suggest an asso-
ciation between CVD risk and treatment type.33 40 In one
study, the risk of ischaemic stroke was stratified by steroid
use, and a statistically significant increase in relative risk
was identified only in patients with concomitant steroid
use.40 A more recent study stratified the relative risk of
stroke and venous thromboembolism into four treat-
ment subgroups: no therapy, disease-modifying anti-
rheumatic drugs (DMARDs), non-steroidal anti-
inflammatory drugs (NSAIDs) and corticosteroids.33
The relative risk of composite stroke was shown to be
highest in those treated with NSAIDs or corticosteroids
followed by those treated with DMARDs. However, these
differences were not statistically significant. In addition,
our meta-analysis included one study that investigated
the effects of end-stage renal disease (ESRD) on the
relative risk of ischaemic heart disease (IHD) in patients
with SLE and identified a higher relative risk of IHD in
patients with ESRD.34
A future synthesis of the available evidence for specified
subgroups among patients with SLE would be useful in
highlighting potential modifiable risk factors for CVD.
CONCLUSION
The risk of stroke and MI events among adult patients
with SLE is twofold to threefold higher compared with
the general population or healthy controls. Known MI
and stroke risk factors and SLE-related factors are likely to
be associated with the observed elevated risk. Under-
standing the various mechanisms underlying increased
CVD risk in patients with SLE, including how antipho-
spholipid antibodies or antiphospholipid syndrome may
modify this risk, will support prevention and treatment
strategies and advance informed patient and physician
decisions.
RMD Open
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